Archive · 3 Sep 2025
US Considers 200% Tariffs on Indian Pharmaceuticals
The United States is thinking about putting very high taxes on medicines imported from India.
These taxes could be as high as 200%.
The US wants to make its own medicine because it had trouble getting enough during the pandemic.
Indian drug companies make a lot of medicine that the US uses, and these taxes could make the medicine much more expensive.
Some experts think the US won't make the taxes that high because it would cause medicine shortages and make it harder for people to get the medicine they need.
Indian companies may explore other markets, like Asia-Pacific, Latin America, ASEAN, and Africa.
The US is considering tariffs up to 200% on imported pharmaceuticals.
The tariffs are proposed under national security provisions.
Indian generic drugs make up about 35% of US market revenue.
Telangana is expected to be the hardest-hit Indian state.
Experts debate the likelihood and impact of the tariffs.
- Who
- US government and Indian pharmaceutical companies
- What
- Proposed tariffs of up to 200% on imported medicines from India
- When
- Ongoing discussions, no date specified
- Where
- United States
- Why
- To boost domestic drug manufacturing due to COVID-19 vulnerabilities.
Indian Pharmaceutical Industry
US Government
Impact of Tariffs
Indian Pharmaceutical Industry
Tariffs will hurt Indian companies and US consumers.
US Government
Tariffs are necessary to protect US national security and manufacturing.
Likelihood of High Tariffs
Indian Pharmaceutical Industry
Unlikely due to potential shortages and consumer impact.
US Government
The tariffs are under consideration.
- Proposed Tariff Rate
- Up to 200%
- US Justification
- National Security, Domestic Manufacturing
- Indian Pharma's US Revenue
- ~35%, ~$10.7 billion
- Key Affected State
- Telangana
- Telangana's Pharma Contribution
- 35% of India's Production, 40% of Exports
